According to the AP (11/2, Tanner), psilocybin “may ease depression in some hard-to-treat patients, a preliminary study” involving 233 adults revealed. While “the effects were modest and waned over time…they occurred with a single experimental dose in people who previously had gotten little relief from standard antidepressants.” The findings of the phase 2 trial were published online Nov. 2 in the New England Journal of Medicine.  Reuters (11/2, Grover) reports the findings “showed that patients who were given the 25 mg dose of psilocybin had statistically significant lower levels of depressive symptoms three weeks after the treatment than people treated with lower doses,” and “about 29% of patients in that group achieved remission on a standardized depression scale.”   NBC News (11/2, Edwards) and CNN (11/2, LaMotte) also report. (SOURCE: APA Headlines)